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Abstract
Treatment choices for cervical cancer are primarily based on clinical FIGO stage and the post-operative evaluation of
prognostic parameters including tumor diameter, parametrial and lymph node involvement, vaso-invasion, infiltration
depth, and histological type. The aim of this study was to evaluate genomic changes in bulky cervical tumors and their
relation to clinical parameters, using single nucleotide polymorphism (SNP)-analysis. Flow-sorted tumor cells and patient-
matched normal cells were extracted from 81 bulky cervical tumors. DNA-index (DI) measurement and whole genome SNP-
analysis were performed. Data were analyzed to detect copy number alterations (CNA) and allelic balance state: balanced,
imbalanced or pure LOH, and their relation to clinical parameters. The DI varied from 0.92–2.56. Pure LOH was found in
$40% of samples on chromosome-arms 3p, 4p, 6p, 6q, and 11q, CN gains in.20% on 1q, 3q, 5p, 8q, and 20q, and losses on
2q, 3p, 4p, 11q, and 13q. Over 40% showed gain on 3q. The only significant differences were found between histological
types (squamous, adeno and adenosquamous) in the lesser allele intensity ratio (LAIR) (p = 0.035) and in the CNA analysis
(p = 0.011). More losses were found on chromosome-arm 2q (FDR= 0.004) in squamous tumors and more gains on 7p, 7q,
and 9p in adenosquamous tumors (FDR= 0.006, FDR= 0.004, and FDR= 0.029). Whole genome analysis of bulky cervical
cancer shows widespread changes in allelic balance and CN. The overall genetic changes and CNA on specific chromosome-
arms differed between histological types. No relation was found with the clinical parameters that currently dictate
treatment choice.
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Introduction
Prognostic factors for cervical cancer
Cervical cancer is one of the most frequent gynecological
cancers worldwide. Following the surgical treatment of cervical
tumors, prognostic factors for survival include the clinical
parameters FIGO stage, tumor diameter, tumor in the parametria,
tumor positive pelvic lymph nodes, vaso-invasion, and infiltration
depth. Histological type is also related to prognosis, and is
evaluated both pre- and postoperatively [1–4]. Although param-
eters can be partly determined pre-operatively by clinical
examination, imaging, or the pathological evaluation of biopsy
specimens, most parameters are only definitively established
following the post-operative pathological examination of surgical
specimens. Presence or absence of these factors is of prognostic
relevance and is therefore used to select both the primary
treatment, and to decide whether adjuvant chemotherapy and/
or radiotherapy are necessary.
Surgical treatment is considered to be the optimal primary
treatment for small diameter cervical tumors (,4 cm, FIGO stage
,1b2). Locally extended tumors (FIGO 2b or higher) are
primarily treated by chemo-radiation. There is, however, no
worldwide agreement on the optimal primary treatment for bulky
cervical cancer (diameter .4 cm, FIGO $1b2–2b), although
radiotherapy or surgery are options [5–13]. Recently, our group
reported a possible additional prognostic factor for bulky cervical
tumors. Patients with barrel-shaped (lateral extension $1.56
craniocaudal extension) bulky tumors showed a worse disease-free
and overall survival after surgical treatment, when compared to
exophytic (all other) tumors. Primary surgical treatment, rather
than radiotherapy or chemo-radiation, has been proposed as the
optimal treatment for patients with exophytic bulky tumors [14].
The ability to select more homogenous subgroups of patients
with cervical tumors may help in the selection of the most suitable
treatment strategy for individual patients. Identification of patients
with specific genetic patterns might be a way to achieve this goal.
Genetic changes could be objectively assessed, pre-operatively, in
tumor biopsies, potentially providing a more accurate prediction
of stage and clinical behavior than the physical examination of the
patient. Furthermore, genetic profiling could provide information
on the genes or pathways responsible for tumor growth and
metastasis.
Genetic profiling
The progression of normal cells to cancer is accompanied by
changes in DNA, and genetic profiles have been established for
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several types of cancer. These profiles have been largely
determined using arrayCGH, and have therefore been limited to
copy number changes. In this study, we used single nucleotide
polymorphism (SNP) arrays to determine the genetic profile of
flow-sorted tumor populations. This approach has the advantage
of also determining allele-specific changes, in addition to copy
number alterations (CNA), in pure tumor cells. In order to include
loss of heterozygosity (LOH) in the analysis, we developed the
lesser allele intensity ratio (LAIR) approach, which allows the
assessment of discrete allele specific copy numbers (CN) for all
genomic locations [15]. This method allows the classification of
the discrete total CN as both the sum of two alleles and as the
balance state, which can then be divided into 3 classes: balanced,
imbalance, and LOH.
The statistical analysis of differences in genetic profiles between
groups of tumors has proven to be difficult. The nature of the
genetic changes in tumors causes strong correlations between
measurements from neighboring probes, correlations that are not
properly handled in commonly used statistical tests. In this study
we introduce a statistical method based on the global test [16],
which performs multiple testing correction correctly in the
presence of strongly correlated values. Another advantage of the
global test is that it can test the hypothesis that groups of samples
are the same on a whole genome level, and can zoom in on
chromosome arms when a difference between groups is found.
Aim of the study
The purpose of this study was to identify genetic changes
associated with one or more prognostic factors in cervical cancer
patients. Our approach was to use SNP array analysis on flow-
sorted FFPE tumor tissue from bulky cervical cancers.
To our knowledge, this is the first large scale, whole genome
SNP array study of this stage of cervical tumors, and no
publication has yet described a genomic profile of cervical tumors
based on the SNP array analysis of pure tumor tissue.
Additionally, this is the first whole genome SNP array study of a
large group of bulky cervical tumors in relation to genetic changes
in balance state and CN, and their relationship to unfavorable
prognostic factors.
Materials and Methods
Samples
Tissue from 107 cervical carcinomas, as well as paired normal
(non-affected) endometrial and/or lymph node tissue, was
obtained from the FFPE tissue bank of the Department of
Pathology, Leiden University Medical Center (LUMC). Samples
were handled in accordance with the medical ethical guidelines
described in the Code Proper Secondary Use of Human Tissue
established by the Dutch Federation of Medical Sciences (www.
federa.org). Our study group consisted of patients living in the
Netherlands and in Suriname. All patients who presented with
bulky cervical cancer FIGO stage $1b2–2b and received primary
surgical treatment at the LUMC between January 1984 and
November 2000, were included in the study group. A large
number of clinical parameters have been characterized in these
patients, but for this study we choose to investigate seven clinical
parameters known to be of prognostic value: tumor diameter,
histological type, parametrial involvement, pelvic lymph node
status, vaso-invasion, infiltration depth, and growth pattern. The
growth pattern was defined as barrel-shaped if the lateral
extension of the tumor was $1.56 the craniocaudal extension of
the tumor; otherwise the tumor was classified as exophytic.
Histological typing (squamous, adeno, adenosquamous, or mixed
tumors) was based on histochemical staining with H&E, periodic
acid-Schiff (PAS) reagent, and Alcian blue for mucin detection.
The use of this additional staining is well established among
Pathologists [17]. FIGO stage was not included in the analyses
since the various postoperative characteristics are overlapping
with, and more accurate than the characteristics that are used for
the pre-operative FIGO staging.
Tissue sample preparation
Paraffin sections taken from all samples were H&E stained and
reviewed by a pathologist (GJF). The tumor nodule was marked on
the H&E section, which was used as a guide to trim the normal
tissue from paraffin block prior to flow cytometric workup. The
tumor negative status of blocks containing normal tissue (either
tumor negative lymph nodes or endometrial tissue) was reviewed
by histology and confirmed. Cell suspensions were prepared for
flow cytometry, as described in detail elsewhere [18,19]. Briefly,
six to ten 60 mm sections were taken from each paraffin block.
Sections were dewaxed and further processed until a cell
suspension was obtained. Cells were then harvested, washed,
counted and stored on ice prior to further processing.
Immunocytochemistry of cell suspensions
Immunocytochemistry has been described in detail elsewhere
[18,19]. Briefly, five million cells were incubated in a mixture of
monoclonal antibodies directed against keratin or vimentin. The
following MAbs were used: anti-keratin MNF116 (DAKO,
Glostrup, Denmark), anti-keratin AE1/AE3 (Millipore-Chemicon,
Billerica, MA), and anti-vimentin V9-2b (diluted 1:5) (Antibodies
for Research Applications BV, Gouda, The Netherlands). Cells
were incubated with premixed FITC- or RPE-labeled secondary
reagents (Goat F(ab2)’ anti-mouse IgG1-FITC and goat F(ab2) ’
anti-mouse IgG2b-RPE [Southern Biotechnology Associates,
Birmingham, AL]), and DNA was labeled with DAPI (Sigma-
Aldrich, Zwijndrecht, Netherlands) [20].
Flow cytometry and sorting
Using an LSRII (BD Biosciences, Erembodegem, Belgium) flow
cytometer, a gate was created to collect 20,000 keratin-positive
single cell events during acquisition. Standard filter sets were used
for the detection of FITC, R-PE and DAPI fluorescence. A data
file contained all events. The WinList 6.0 and ModFit 3.2.1
software packages (Verity Software House, Inc., Topsham, ME)
were used for data analysis and DNA index (DI) calculation
(median of G0G1 population of tumor cell fraction / median of
G0G1 population of stromal cell fraction). In order to separate
tumor cells from genetically normal cells (connective tissue,
lymphocyes and blood vessels) [21,22]. keratin-positive and
vimentin-positive normal cells were collected separately, using a
FACSAria I flow-sorter at 40 psi (BD Biosciences, Erembodegem,
Belgium). In cases where flow cytometry detected more than one
population of keratin-positive tumor cells, both populations were
sorted independently. The most prevalent DNA population was
selected to undergo SNP array analysis.
DNA isolation was performed as previously described [23]. In
cases where endometrial or lymph node tissue was not available,
DNA from sorted tumor stroma cell fractions was used as a
reference [23].
SNP array
The Golden gate Linkage panel V, consisting of 4 arrays with a
total of 6000 SNPs (Illumina, San Diego, USA), was used to
analyze tumor-derived DNA, together with DNA from matched
LOH and CNA in Bulky Cervical Cancer
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normal/non-affected tissue. Assays were performed as previously
described [24]. The resolution of this assay is relatively low, but in
contrast with other SNP assays it can be used with FFPE derived
DNA [24,25]. These SNP analyses on FFPE tissue were
extensively validated previously by FISH analysis [15,24–26].
Samples were processed in 6 batches of 48 samples, and samples of
the same patient were always processed in the same batch. A 7th
batch was used to repeat assays with low quality. The samples
were genotyped in Illumina Beadstudio 2.3. The reference
genotype clusters were derived from the normal samples in the
dataset, and genotypes and allele intensities were extracted. The
beadarraySNP package was used for further data processing. The
analysis steps are depicted in Figure 1. SNPs that deviated
significantly from Hardy-Weinberg equilibrium (at a significance
level of 0.05, divided by the number of SNPs analyzed = 0.00001),
and SNPs with a call rate lower than 95% in controls, were
removed to prevent the possibility of genotyping errors. All assays
with a median intensity of below 2000 for one of the alleles were
rejected and repeated in batch 7. Normalization was subdivided in
4 steps: I) normalize intensities for dye effect – quantile
normalization was applied to make the distribution of the
intensities for both dyes identical, II) per sample between assay
quantile normalization to equalize intensity differences, III) within
sample normalization to scale the median intensity of each allele to
1, IV) per SNP between sample normalization using the reference
samples (which scales the total intensity of SNPs and corrects the
allele specific bias by using a linear model between the B-allele
ratio and total intensity). Matched normal samples were used to
select the informative heterozygous SNPs. The LAIR was
calculated for all informative SNPs in the tumor samples. The
LAIR value is basically the B-allele ratio, the ratio of the intensity
of the B-allele and the total intensity, mirrored on its symmetry
axis at 0.5, and scaled to a value between 0 and 1. This makes it
easy to compute averages and enables segmentation. In order to
identify genomic regions with identical CN and balance state, the
data were segmented using circular binary segmentation at the
default settings of the DNAcopy R package [27]. For each tumor,
first the signal intensity of each chromosome was segmented,
followed by a sub-segmentation of the previously obtained
segments of the LAIR [15]. By combining the continuous CN
(signal intensity) and the LAIR value of a segment with the sample
DNA index measured by flow cytometry, we developed a new
calling method that assigns an allelic state to each segment [15]. In
the present study allelic state was distinguished along 2 dimen-
sions. For each segment, discrete CN and a balance state was
assigned. The discrete CN is an absolute measure assigned to
segments in such a way that the average discrete CN values across
all segments should reflect the sample DNA index. The balance
between alleles was divided in 3 possible outcomes: balanced
segments – with the same CN for both alleles and a LAIR value
near 1; LOH – segments with only one allele present and a LAIR
value near 0; imbalanced segments – with different CN for the two
alleles and a LAIR value between 0 and 1.
Statistical analysis
The breakpoints between segments are different in every
sample. The breakpoints of each sample were applied to all
samples. This makes the samples comparable after segmentation
The global test was used to detect differences in genetic changes
between groups of patients at the whole genome level and in
chromosomal arms [16]. We tested differences both in continuous
and discrete CN. The continuous CN is a relative measure; the
sample average is 1 regardless of the DI. Discrete CN is an
absolute measure that represents the number of copies in a
genomic segment in each cell of a tumor. The continuous CN is
the conventional way of looking at CN; we would investigate here
whether it is useful to look at absolute CN. LAIR as a continuous
measure of allelic balance and balance state as a discrete measure
were also tested. Continuous CN gains and losses were defined as
deviating more than 15% from the sample average. The global test
allows the use of confounders. Ethnic group was used as a
confounder for all tests, because the genetic make up could
influence the occurrence of chromosomal changes. DI was used as
an extra confounder in the analysis of continuous CN, because DI
has a relationship with gains and losses. The determination of
discrete CN already takes the DI into account, and therefore using
DI as a confounder would render this analysis back to a relative
measure instead of an absolute (see Figure S2 in File S1). Ethnicity
was defined by clustering the genotypes together with HapMap
samples of known ethnic origin. The tests were further localized by
performing the global test on all chromosomal arms individually.
Differences between groups were accepted as significant when the
false discovery rate (FDR) was lower than 0.05 [28].
All of our SNP-data can be found in the Gene Expression
Omnibus: series GSE29143.
Figure 1. Analysis steps for SNP array data with the Illumina
Beadstudio and the beadarraySNP package. The data is
preprocessed to obtain quality checked and normalized values for
intensity and LAIR. Together with the DNA-index these are interpreted
on a discrete and categorical scale. The embedded plot shows
normalized intensity as dots in the upper panel, and LAIR in the lower
panel as hyphens. The segmentation procedure has divided this region
in two segments. The left segment has copy number 1 with LOH. The
allelic state is A. The right segment has copy number 2 with balance.
The allelic state is AB.
doi:10.1371/journal.pone.0067414.g001
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Results
Clinical data
From the 107 cervix carcinoma patients included in the study,
sufficient DNA material was obtained for 82 matched tumor/
normal pairs after flow sorting. One sample was removed after
hybridization due to low data quality. Table 1 shows summarized
clinical information on the 81 patients analyzed, while Table S1 in
File S1 shows the data for individual patients. As 96.3% of the
tumors were found to have a tumor diameter larger than 40 mm,
this parameter was not explored further.
Principal Components Analysis (PCA) was performed using the
4 original HapMap populations as reference panels, together with
genotypes obtained from the patients’ normal tissue. Three major
genetic clusters could be distinguished in the four HapMap
populations, with the Japanese and Chinese HapMap populations
clustering together. Guided by this clustering, we classified the
patients into 3 ethnic groups: European (EUR, n= 45) for patients
that cluster together with the CEU HapMap population, African
(AFR, n= 25) that cluster together with YRI, and Asian (ASI,
n = 11) that cluster together with the CHB and JPT populations.
For more detailed information, see Figure S1 in File S1.
Samples
Most of the 81 matched tumor samples (89%) could be paired
with normal/non-affected tissue. As normal tissue was not
available in 9 cases, the tumor DNA was instead paired with the
DNA from normal stroma cells obtained from the flow sorting
procedure [23]. Cell sorting detected the presence of more than
one tumor cell population in 8 cases. For these cases, the most
prevalent DNA population was selected to undergo SNP array
analysis. The DNA-index (DI) of flow-sorted samples varied from
0.92 to 2.56. Figure 2 shows the DI density plot of the patient
group.
Overall genetic pattern
Balance State. When looking at the balance state patterns
generated by the analysis of the SNP array data, it can be observed
that LOH is present in almost all chromosomal regions (Figure 3).
On 28 out of 40 chromosome arms, more than 10% of the patients
showed LOH. LOH was particularly frequent on chromosome
arms 3p, 4p, 6p, 6q, and 11q, where it was observed in more than
40% of all patients. Besides LOH all chromosomal regions show
the presence of imbalances in at least 10% of the samples
(Figure 3). The pattern of imbalance is somewhat complementary
to the pattern of LOH.
Copy number alterations. CNA using the continuous CN
can be seen throughout the genome (Figure 4). More than 20% of
the patients show gains on 1q, 3q, 5p, 8q, and 20q and losses on
chromosomes 2q, 3p, 4p, 11q, and 13q. Gain on 3q was found in
.40% of all samples.
Table 1. Clinical data of 81 SNP analyzed patients.
Mean Min – Max
Age (yrs) 47 25–87
N %
Place of residence Netherlands 47 58
Surinam 32 39.5
Other 2 2.5
Ethnic cluster European 45 55.6
African 25 30.9
Asian 11 13.6
FIGO stage 1b2 59 72.8
2a 19 23.5
2b 3 3.7
Histological type squamous carcinoma 52 64.2
Adenocarcinoma 3 3.7
adenosquamous carcinoma20 24.7
other/mixed 6 7.4
Growth pattern Exophytic 40 49.4
barrel shaped 41 50.6
Infiltration
depth
0–5 mm 4 4.9
6–10 mm 11 13.6
11–15 mm 16 19.8
.15 mm 44 54.3
Tumor diameter 21–40 mm 1 1.2
.40 mm 78 96.3
Unknown 2 2.5
Tumor in
parametria
No 57 70.4
Yes 24 29.6
Tumor in
lymphnodes
No 47 58
Yes 34 42
Vaso-invasion No 36 44.4
Yes 39 48.1
Unknown 6 7.4
doi:10.1371/journal.pone.0067414.t001
Figure 2. Distribution of the DNA index in 81 cervical tumor
samples. There is a bimodal distribution of the DNA index with peaks
around 1, and close to 2.
doi:10.1371/journal.pone.0067414.g002
LOH and CNA in Bulky Cervical Cancer
PLOS ONE | www.plosone.org 4 July 2013 | Volume 8 | Issue 7 | e67414
Relation between clinical parameters and genetic
changes
Balance state. Table 2A shows the results of the whole
genome analysis of LAIR and the balance state. When the 22
autosomes and the X chromosome were analyzed together, only
histological type showed statistically significant differences in
LAIR value (p = 0.035). No differences between the different
clinical parameters were observed in balance state (p = 0.050).
Focusing on the chromosome arms individually showed that the
difference between histological groups could not be attributed to a
specific chromosome arm.
Copy number alterations. Table 2B shows the result of the
whole genome analysis for changes in CN. Continuous CN values
showed statistically significant differences only for histological
types (p = 0.011). The test for discrete CN was not statistically
significant (p = 0.363). When DI is added as a confounder to the
analysis of discrete CN the difference between histological types is
significant (p = 0.019), The discrete CN profiles of patients with
and without lymph node metastasis were significantly different
(p = 0.032), and here the test for continuous CN was not significant
(p = 0.614). The inclusion of DI as a confounder in the test for
discrete CN now shows no difference anymore (p = 0.637). See
also Figure S3 in File S1. For continuous CN the tests show
comparable results with or without inclusion of DI as a confounder
(data not shown). We then zoomed in on individual chromosome
arms when analyzing the clinical parameters that showed a
difference. Squamous tumors showed greater losses on 2q
(FDR=0.004), while adenosquamous tumors were found to have
more gains on 7p, 7q, and 9p (FDR=0.006, FDR=0.004, and
FDR=0.029 respectively). For discrete CN, the differences
between groups with and without lymph node involvement could
not be attributed to any of the chromosome arms in particular.
Figure 3. Overall frequency of imbalance and LOH per chromosome. Besides the height of the graph, The colors indicate the frequency of
LOH; black: .10%, green: .20%, blue: .0%, red: .40%. The balanced group is not plotted; it is the complement of these 2 groups.
doi:10.1371/journal.pone.0067414.g003
Figure 4. Frequency of gains and losses. Gains are depicted on top
of the ideograms, while losses are depicted below. The colors indicate
the frequency within the dataset; black: .10%, green: .20%, blue:
.30%, red: .40%. Gains and losses were identified when the
continuous CN deviated more than 15% from the sample average.
doi:10.1371/journal.pone.0067414.g004
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Figure 5 shows the differences in continuous CN for histological
type on the different chromosome arms.
Discussion
Using SNP array analysis, we have shown extensive genome-
wide LOH and CN changes in bulky cervical cancer. To our
knowledge, no previous studies have applied genome-wide genetic
profiling to such a large number of bulky cervical cancers (FIGO
stage 1b2–2b).
The analysis of the relation between genetic changes and the
prognostic factors histological type, infiltration depth, lymph node
status, extension to the parametria, vaso-invasion, and growth
pattern revealed a statistically significant difference in the analysis
of the discrete CN between groups with and without lymph node
involvement, and a relationship between histological type and
changes in LAIR and continuous CN. Even though the discrete
CN did not show differences between the different histological
types, we observed that when the DNA index was used as a
confounder in the analysis the significant difference between the
histological groups was restored (p-value goes from 0.363 to
0.019). This signifies that the discrete CN values contain ample
information to distinguish the groups, but that relative changes in
DNA compared to the average DNA content of a cell are more
important for the difference between histological groups than the
absolute allele count.
In order to specify the genetic changes that contribute to the
differences in clinical parameters, we analyzed chromosome arms
individually. In the analysis of continuous CN changes, the
histological group squamous carcinomas showed a statistically
significant increase in loss on 2q, while adenosquamous carcino-
mas showed more gains on 7p, 7q, and 9p. The statistical
differences in these 4 regions are comparable, but the numerical
difference is most pronounced for chromosome 2q, where around
10% of the adenosquamous carcinomas shows loss, but over 40%
of the squamous carcinomas shows loss. Despite the whole genome
difference in discrete CN between patients with and without
lymph node involvement, we could not link this difference to a
specific chromosomal arm. Thus, this difference cannot be used to
extract a clinical parameter.
CNA were found in previous studies using classical array-CGH,
which examines only continuous CN changes (see Table S2 in
File S1) [29–39]. As can be seen in the Table, the gains that we
found were previously reported:
Gains on 1q were also found in 8 of the 11 included studies, on
3q frequently in all of the studies, on 5p in 5 of the 11 studies, on
8q in 3 of the other studies, and on 20q in 6 studies. The losses on
2q were reported in 5 of the 11 other studies, on 3p in 8 of 11, on
4p in 6, on 11q in 6, and on 13q in 8 of the other studies. All of our
findings were previously found by Rao et al., and all but one by
Lando et al., although additional changes on other locations were
also found in these studies. This might be explained by the
inclusion of tumors with a higher FIGO stage in these studies.
Some of the studies also investigated the relation between
clinical parameters and genetic changes in cervical cancer (see
Table S2 in File S1) [29,30,33,34,36]. Rao et al. found no
differences between squamous and adeno tumors stage 1b–4b.
This may be due to the small number of adenocarcinomas
included (5 adenocarcinomas and 72 squamous carcinomas) [34].
There were no adenosquamous tumors in this group. In an
analysis of stage 1b–3b cervical tumors, Wilting et al. reported
significantly more gains in 9 squamous tumors as compared to 7
adenocarcinomas. Higher gains were predominantly found on 3q
[36], although the method used to define the histological type was
not described. The locations of the differences in genetic
alterations between squamous and adenosquamous carcinomas
Table 2. Whole genome analyses of genetic changes and clinical parameters.
A. Whole genome analysis of balance *
LAIR Allelic Balance
Clinical parameter p-value p-value
Growth pattern 0.244 0.184
Histological type 0.035 0.05
Infiltration depth 0.651 0.509
Lymphnodes 0.626 0.683
Parametria 0.928 0.769
Vasoinvasion 0.146 0.301
B. Whole genome analysis of Copy Number *
Continuous variables Discrete variables
extra confounder DI
Clinical parameter p-value p-value p-value
Growth pattern 0.346 0.209 0.396
Histological type 0.011 0.363 0.019
Infiltration depth 0.397 0.967 0.338
Lymphnodes 0.614 0.032 0.637
Parametria 0.695 0.383 0.654
Vasoinvasion 0.213 0.744 0.083
*confounder: Ethnic cluster.
doi:10.1371/journal.pone.0067414.t002
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in our study did not coincide with the findings of Wilting et al., but
there were no adenosquamous tumors in this group.
The difference in overall findings between our and previous
studies may be explained by differences in FIGO stage, sample
size, and staining techniques to discriminate histological type. The
group of tumors that we used was not previously analysed in the
literature, and, except for lymph nodes, the clinical parameters
that we analysed were studied before in only 2 of the other 11
studies (Rao et al., and Wilting et al.). Dilution caused by the use of
tumor tissue instead of pure tumor cells may also explain
differences in results.
The prognostic relevance of histological type is still an object of
debate and is not currently used for primary or adjuvant treatment
choice [1–4,40–42]. The conflicting results of these studies on the
effect of histological type on tumor behavior and patient survival
may also be due to differences in the classification of tumors,
where no specific staining (PAS and Alcian blue) was applied.
Future studies on genomic alterations are advised to take the
different genetic profiles of histological types into consideration.
The regions with the most prominent differences contain many
genes. The aim of this study was to find additional pre-operative
parameters that could be used for treatment choice, without
knowing the causative gene. This topic deserves further investi-
gation.
The SNP array used in this study consisted of 6000 SNP
markers distributed evenly over the genome, and the array was
optimized to have a higher minor-allele frequency in the
Caucasian (European) population. As a consequence, the average
number of informative probes was higher for the Caucasian
patients (2139 informative SNPs) than for the African (1796) and
Asian (1712) patients. This may result in an underestimation of the
genetic changes that take place in cervical cancer in these
populations. Although it would have been interesting to compare
genetic changes and the relationship to clinical parameters by
ethnic background, the subgroups are too small to allow this.
Our results revealed genetic changes related to histological type,
a clinical parameter not currently used for treatment choice. Our
analysis showed no relation of genetic changes to clinical
parameters that could be used to predict unfavorable post-
operative prognostic characteristics or select subgroups of patients.
It seems that, at present, the best evaluation of prognostic factors
still comes from pre-, intra-, and post-operative findings of the
Figure 5. Frequency of gains and losses in histological groups. Gains are depicted on top of the ideograms, while losses are depicted below.
Red: squamous tumors, green: adenocarcinoma + mixed type, blue: adenosquamous tumors. Adenocarcinoma and mixed type were combined
because of the low numbers of samples in these groups.
doi:10.1371/journal.pone.0067414.g005
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gynecologic oncologist and pathologist. As differences in DNA
alterations between tumors of different histological types may have
an impact on tumor behavior, treatment response and survival,
future research should include larger patient groups, and use
staining techniques that can reliably distinguish histological type.
Supporting Information
File S1 Figure S1, Classification of patient ethnicity in
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